Evidence map›Paper›PMID 27235858›Full record

ArticleGynecologic oncology2016

Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.

Lidia Hernandez, Marianne K Kim, L Tiffany Lyle, Kristen P Bunch, Carrie D House, Franklin Ning, Anne M Noonan, Christina M Annunziata

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gynecologic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed
3.3field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 118 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. VERU-111, an orally available tubulin inhibitor, suppresses ovarian tumor growth and metastasis.The Journal of pharmacology and experimental therapeutics · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Lidia HernandezWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, United States.
Marianne K KimWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, United States.
L Tiffany LyleWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, United States.
Kristen P BunchWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, United States.
Carrie D HouseWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, United States.
Franklin NingWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, United States.
Anne M NoonanWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, United States.
Christina M AnnunziataWomen's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, United States. Electronic address: annunzic@mail.nih.gov.
National Cancer Institute · US

Funding

Nuclear Factor-kappaB in Ovarian CancerZIABC011054 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ANNUNZIATA, CHRISTINA · 2009 to 2023
$12.1M
Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC011054
6 · The paper itself

Abstract

objectiveThe value of cell lines for pre-clinical work lies in choosing those with similar characteristics. Selection of cell lines is typically based on patient history, histological subtype at diagnosis, mutation patterns, or signaling pathways. Although recent studies established consensus regarding molecular characteristics of ovarian cancer cell lines, data on in vivo tumorigenicity remains only sporadically available, impeding translation of in vitro work to xenograft models.

methodsWe introduced 18 ovarian cancer cell lines into athymic nude mice through subcutaneous, intraperitoneal, and ovary intrabursal routes, and observed tumor development over 6weeks. We also profiled cell line gene expression and identified differentially expressed gene sets based on their ability to form tumors in the subcutaneous or intraperitoneal locations. Representative cell lines were further subjected to proteomic analyses.

resultsOvarian cancer cell lines showed variable ability to grow in mice when implanted subcutaneous, intraperitoneal, or intrabursal. While some cell lines grew well in both SC and IP locations, others showed a strong propensity to grow in one location only. Gene expression profiles suggested that cell lines showing preference for IP growth had gene expression patterns more similar to primary tumors.

conclusionsWe report the tumorigenicity of 17 human ovarian cancer cell lines and one mouse cell line in three distinct anatomical locations, and associated gene networks. Growth patterns and histopathology, linked to molecular characteristics, provide a valuable resource to the research community, and better guide the choice of cell lines for in vitro studies to translate efficiently into xenograft testing.

Indexed as

Cell Line, TumorAnimalsDrug Screening Assays, AntitumorFemaleHeterograftsHumansMiceNeoplasm TransplantationOvarian NeoplasmsXenograft Model Antitumor AssaysCell linesMouse modelOvarian cancerXenografts

Identifiers

PMID27235858
PMCPMC4961516
OpenAlexW2399911066

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.